Table 1.
Baseline characteristics of CHB cohort.
| Variables | Total (n = 300) | ACLF (n = 108) | non-ACLF (n = 192) | p value |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age (year) | 45.0 ± 12.0 | 46.18 ± 11.89 | 44.40 ± 11.99 | 0.217 |
| Male, n (%) | 255 (85.0) | 94 (87.0) | 161 (83.9) | 0.459 |
| HBV reactivation (%) | 65 (21.7) | 15 (13.9) | 50 (26.0) | 0.014 |
| Alcohol intaking, n (%) | 24 (8.0) | 9 (8.3) | 15 (7.8) | 0.873 |
| Heptoxic drug, n (%) | 17(5.7) | 8 (7.4) | 9 (4.7) | 0.328 |
| Fatigue, n (%) | 14 (4.7) | 8 (7.4) | 6 (3.1) | 0.091 |
| UGIB, n (%) | 6(2.0) | 3 (2.8) | 3 (1.6) | 0.470 |
| Cirrhosis, n (%) | 153 (51.0) | 57 (52.8) | 96 (50.0) | 0.644 |
| Ascite, n (%) | 102 (34.0) | 37 (34.3) | 65 (33.9) | 0.943 |
| HE, n (%) | 2(0.7) | 2 (1.9) | 0 (0) | 0.059 |
| HBeAg +, n (%) | 147 (49.0) | 43 (42.2) | 104 (54.2) | 0.455 |
| Treatment data | ||||
| Average Stay time (days) | 21.49 ± 14.59 | 25.10 ± 18.07 | 19.46 ± 11.78 | <0.001 |
| Telipressin therapy, n (%) | 4 (1.3) | 4 (3.7) | 0 (0) | 0.016 |
| Artificial liver support, n (%) | 31 (10.3) | 23 (21.3) | 8 (4.2) | <0.001 |
| NH3 reduction therapy, n (%) | 24 (8.0) | 21 (19.4) | 3 (1.6) | <0.001 |
| Diuretics therapy, n (%) | 85 (28.3) | 32 (29.6) | 53 (27.6) | 0.709 |
| Laboratory parameters | ||||
| WBC (10∧9/L) | 5.8 ± 4.0 | 7.17 ± 5.19 | 5.08 ± 2.82 | <0.001 |
| Neutrophil (10∧9/L) | 4.19 ± 4.05 | 5.36 ± 4.47 | 3.54 ± 3.65 | <0.001 |
| Leukomonocyte (10∧9/L) | 0.56 ± 2.13 | 0.90 ± 3.48 | 0.38 ± 0.46 | 0.122 |
| TBil (mg/dL) | 10.91 ± 9.02 | 18.33 ± 7.94 | 6.72 ± 6.57 | <0.001 |
| ALT (IU/L) | 558.83 ± 749.02 | 631.39 ± 835.16 | 518.02 ± 694.90 | 0.209 |
| AST(IU/L) | 419.34 ± 502.22 | 475.67 ± 584.46 | 387.95 ± 448.53 | 0.148 |
| AKP(IU/L) | 136.42 ± 52.49 | 141.12 ± 55.69 | 134.26 ± 50.97 | 0.322 |
| Alb (g/L) | 32.5 ± 8.9 | 30.38 ± 5.08 | 33.62 ± 10.32 | 0.003 |
| INR | 1.58 ± 0.58 | 2.18 ± 0.53 | 1.24 ± 0.23 | <0.001 |
| Sodium (mmol/L) | 137.07 ± 8.90 | 135.99 ± 6.16 | 137.67 ± 10.08 | 0.119 |
| Kalium (mmol/L) | 4.02 ± 0.57 | 4.06 ± 0.62 | 4.72 ± 9.81 | 0.419 |
| Creatine (mg/dL) | 0.80 ± 0.44 | 0.84 ± 0.57 | 0.77 ± 0.34 | 0.303 |
| Log HBV-DNA(IU/ml) | 4.14 ± 2.75 | 3.94 ± 2.76 | 4.26 ± 2.75 | 0.348 |
| Sexual hormones | ||||
| E2 (pg/ml) | 98.81 ± 82.11 | 144.22 ± 76.82 | 73.15 ± 73.60 | <0.001 |
| TT (ng/ml) | 3.33 ± 3.31 | 1.59 ± 1.69 | 4.32 ± 3.58 | <0.001 |
| Scoring systems | ||||
| Child-Pugh | 8.86 ± 1.92 | 10.51 ± 0.98 | 7.93 ± 1.69 | <0.001 |
| MELD | 14.33 ± 7.76 | 21.30 ± 5.91 | 10.27 ± 5.45 | <0.001 |
| iMELD | 2.80 ± 0.96 | 3.59 ± 0.86 | 2.35 ± 0.69 | <0.001 |
| SOFA | 4.90 ± 2.26 | 7.22 ± 0.98 | 3.58 ± 1.63 | <0.001 |
| CLIF-C ACLF | 32.22 ± 8.92 | 38.38 ± 8.49 | 28.76 ± 7.12 | <0.001 |
| COSSH ACLF | 5.08 ± 0.97 | 5.99 ± 0.88 | 4.55 ± 0.52 | <0.001 |
AKP, phosphatase alkaline; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIF-C ACLF, European Association for the Study of Chronic Liver Failure; COSSH ACLF, ACLF model of Chinese Group on the Study of Severe Hepatitis B; E2,estradiol; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HE, hepatic encephalopathy; INR, international normalized ratio; MELD, Model for End-stage Liver Disease; SOFA, sequential organ failure assessment; TT, testosterone; UGIB, upper gastrointestinal hemorrhage; WBC, white blood count.